Ripretinib (Qinlock®) – Gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies
Characteristics
| Start date | 01.01.2022 |
|---|---|
| Resolution | 16.06.2022 |
| INN | Ripretinib |
| Brand name | Qinlock® |
| Pharm. company | Deciphera Pharmaceuticals (Netherlands) B.V. |
| G-BA procedure ID | 2022-01-01-D-782 |
| Therapeutic area | Oncological diseases ORPHAN |
| Reason for procedure | Initial assessment |
| Indication (German) |
|---|
|
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Adults with advanced gastrointestinal stromal tumours (GIST) who have previously received treatment with three or more kinase inhibitors, including imatinib. | – (Orphan drug) |
9. Associated procedures
| Resolution | INN | Brand name | Indication | Patients | Additional benefit |
|---|---|---|---|---|---|
| 01.01.2022 – 16.06.2022 | Ripretinib | Qinlock® | Gastrointestinal stromal tumours (GIST), ≥ 3 prior therapies | 220 – 300 |
<< List of all resolutions